Document detail
ID

doi:10.1186/s12931-022-02265-6...

Author
Dupont, Axelle Couffignal, Camille Arias, Camila Salah, Kankoe Phillips-Houlbraq, Mathilde Le Brun, Mathilde Taillé, Camille
Langue
en
Editor

BioMed Central

Category

Medicine & Public Health

Year

2022

listing date

12/14/2022

Keywords
asthma covid-19 influenza prognosis clinical data warehouses 95% hospitalized 2017–2018 2018–2019 ci factors risk asthma influenza covid-19
Metrics

Abstract

Background At the time of the SARS-CoV-2 emergence, asthma patients were initially considered vulnerable because respiratory viruses, especially influenza, are associated with asthma exacerbations, increased risk of hospitalization and more severe disease course.

We aimed to compare the asthma prevalence in patients hospitalized for COVID-19 or influenza and risk factors associated with poor prognosis with the diseases.

Methods This retrospective cohort study used the Paris university hospitals clinical data warehouse to identify adults hospitalized for COVID-19 (January to June 2020) or influenza (November 2017 to March 2018 for the 2017–2018 influenza period and November 2018 to March 2019 for the 2018–2019 period).

Asthma patients were identified with J45 and J46 ICD-10 codes.

Poor outcomes were defined as admission in intensive care or death.

Results Asthma prevalence was significantly higher among influenza than COVID-19 patients (n = 283/3 119, 9.1%, 95% CI [8.1–10.1] in 2017–2018 and n = 309/3 266, 9.5%, 95% CI [8.5–10.5] in 2018–2019 versus n = 402/9 009, 4.5%, 95% CI [4.0–4.9]).

For asthma patients, 31% with COVID-19 were admitted to an intensive care unit versus 23% and 21% with influenza.

Obesity was a risk factor for the 2017–2018 influenza period, smoking and heart failure for the 2018–2019 period.

Among COVID-19 patients with asthma, smoking and obesity were risk factors for the severe form.

Conclusions In this study, patients with an asthma ICD-10 code were less represented among COVID-19 patients than among influenza-infected ones.

However, outcomes were poorer for COVID-19 than influenza patients, both with asthma.

These data highlight the importance of protective shields and vaccination against influenza and COVID-19 in this population.

Dupont, Axelle,Couffignal, Camille,Arias, Camila,Salah, Kankoe,Phillips-Houlbraq, Mathilde,Le Brun, Mathilde,Taillé, Camille, 2022, Outcomes and risk factors with COVID-19 or influenza in hospitalized asthma patients, BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw